SNDX · XBRL financial data

Syndax Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SNDX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	0*	0	4	13	8*	20	38	46	69*	65	73	83
Research and development	55*	56	49	71	66*	62	62	56	79*	59	68	67
Selling, general and administrative	year only	—	—	—	year only	—	—	—	year only	—	—	—
General and administrative	—	23	29	31	—	41	44	45	—	38	42	44
Total operating expenses	78*	80	78	102	104*	104	107	103	131*	99	113	125
Operating income (loss)	(78)*	(80)	(74)	(90)	(96)*	(84)	(69)	(57)	(63)*	(34)	(40)	(42)
Interest income	6*	7	6	5	7*	7	6	5	4*	4	4	6
Interest expense	0*	0	0	0	5*	0	0	0	0*	0	0	0
Other income (expense)	(0)*	(0)	(0)	0	(0)*	(0)	(1)	(0)	(0)*	(0)	(0)	(0)
Income tax expense (benefit)	—	0	0*	0*	—	0	0*	0*	0*	0	0*	0*
Net income (loss)	(72)*	(72)	(68)	(84)	(94)*	(85)	(72)	(61)	(68)*	(43)	(49)	(49)
Earnings per share, basic USD per share	(1.00)*	(0.85)	(0.80)	(0.98)	(1.09)*	(0.98)	(0.83)	(0.70)	(0.78)*	(0.48)	(0.55)	(0.55)
Earnings per share, diluted USD per share	(1.00)*	(0.85)	(0.80)	(0.98)	(1.09)*	(0.98)	(0.83)	(0.70)	(0.78)*	(0.48)	(0.55)	(0.55)
Weighted average shares, basic millions of shares	73*	85	85	85	87*	86	86	87	87*	88	89	90
Weighted average shares, diluted millions of shares	73*	85	85	85	87*	86	86	87	87*	88	89	90

Fiscal quarters (SNDX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	295	115	105	133	154	154	109	117	135	131	336	136
Short-term investments	275	320	320	257	419	358	347	319	259	221	211	291
Accounts receivable	0	—	—	—	8	—	—	—	38	—	—	—
Inventory	0	—	—	—	0	5	18	25	33	35	33	39
Prepaid and other current assets	3	5	4	5	9	8	10	10	13	16	17	14
Total current assets	581	454	446	415	603	549	532	530	528	471	675	567
Property and equipment, net	0	0	0	0	0	0	0	0	0	0	0	0
Right-of-use asset	1	1	1	1	2	2	2	1	1	1	1	1
Total assets	613	543	477	426	725	641	596	552	530	473	704	693
Accounts payable	10	9	12	5	12	10	17	14	17	11	5	4
Current portion of long-term debt	0	—	—	—	338	336	331	327	350	350	350	350
Total current liabilities	58	51	42	59	104	95	113	114	120	86	100	121
Lease liability, non-current	1	0	0	0	2	—	—	—	—	—	—	—
Total liabilities	59	51	43	59	437	426	439	436	465	431	689	710
Accumulated deficit	(902)	(975)	(1,043)	(1,127)	(1,221)	(1,306)	(1,378)	(1,439)	(1,507)	(1,549)	(1,599)	(1,648)
Total stockholders' equity	554	492	434	366	288	215	157	115	65	42	15	(17)
Total liabilities and equity	613	543	477	426	725	641	596	552	530	473	704	693
Common shares outstanding (cover page) millions of shares	85	85	85	86	86	86	86	87	88	89	89	90

Fiscal quarters (SNDX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(72)*	(72)	(68)	(84)	(94)*	(85)	(72)	(61)	(68)*	(43)	(49)	(49)
Stock-based compensation	8*	9	10*	12*	12*	10	14*	12*	11*	12	14*	15*
Net cash from operating activities	(41)*	(84)	(72)*	(62)*	(57)*	(95)	(88)*	(71)*	(69)*	(50)	(30)*	(27)*
Purchases of property and equipment	year only	—	—	—	year only	—	—	—	year only	—	—	—
Net cash from investing activities	(16)*	(99)	62*	87*	(269)*	94	42*	72*	82*	38	(17)*	(176)*
Net cash from financing activities	258*	2	1*	3*	347*	1	1*	6*	6*	8	253*	3*
Net change in cash	201*	(181)	(9)*	28*	21*	(0)	(45)*	8*	18*	(4)	206*	(201)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Syndax Pharmaceuticals	136	83	(27)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Niagen Bioscience	67	30	2.8*	79.1M	—	Q2 FY26 10-QJun 30, 2026
Cogent Biosciences	181	not reported	(77)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Phibro Animal Health	61	397*	24*	not reported	—	Q4 FY26 10-KJun 30, 2026
Pacira BioSciences	206	192	57*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Wave Life Sciences	197	13	(60)*	197.2M	7.4 quarters	Q3 FY26 10-QSep 30, 2026
Avadel Pharmaceuticals	80	77	22*	97.7M	—	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.